Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

Not particularly. From what I recall (had it on in background mainly), MNTA still plans to partner their FOB platform by end of year which with 3 months left I fully expect them to do so at this point. They want a 50/50 split kind of thing (development costs and profit share) and mentioned they did the offering as leverage for that kind of deal.

He would not comment on Glatopa share (deferred to Sandoz) but did mention IMS is under reporting Galtopa Rx. Asked about sole generic and he seemed pretty confident MNTA will have it for some time, but obivously impossible to tell what other cos have. Good info on the other pipeline programs but nothing new per se.